After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a year of exceptional share price gains.
Overview
Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics (NASDAQ:GLUE), executed the sale of 41,845 shares of Common Stock over June 23 and June 24, 2026, in a transaction structured as an exercise of options immediately followed by open-market disposition, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($21.08); post-transaction value based on June 24, 2026 derived close ($1,250,833.20).
Details
* 1-year performance calculated using June 24, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.